Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq

Published:2017-08-10 Issue:3 Volume:59 Page:459-465
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Rathke Hendrik,Giesel Frederik L.,Flechsig Paul,Kopka Klaus,Mier Walter,Hohenfellner Markus,Haberkorn Uwe,Kratochwil Clemens

Publisher

Society of Nuclear Medicine

Subject

Radiology Nuclear Medicine and imaging

Reference30 articles.

1. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

2. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer;Ross;Clin Cancer Res.,2003

3. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases

4. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

5. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer;Clinical and Translational Oncology;2024-09-12

2. Role of Lutetium Radioligand Therapy in Prostate Cancer;Cancers;2024-07-01

3. Deescalated²²⁵Ac-PSMA-617 Versus¹⁷⁷Lu/²²⁵Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients;Journal of Nuclear Medicine;2024-06-06

4. A case of severe side effects to androgen receptor inhibitor and consequently switch to radioligand therapy in early castration resistant prostate cancer;Urology Case Reports;2024-05

5. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT);European Journal of Nuclear Medicine and Molecular Imaging;2023-05-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3